Press Release for the Financial Results for the quarter and year ended 31 March 2026.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences reported strong FY26 results with revenue from operations growing 29% to ₹2,192 Cr from ₹1,695 Cr in FY25. EBITDA surged 56% to ₹661 Cr, driving EBITDA margin expansion of 500 basis points from 25% to 30%. Net profit (PAT) doubled, up 109% to ₹355 Cr compared to ₹170 Cr in the prior year, with PAT margin improving from 10% to 16%. The growth was driven by deepening engagement with large pharma customers, momentum in integrated discovery services, and investments in new modalities. The company also incurred Capex of ₹633 Cr during the year. Q4 FY26 standalone revenue was ₹602 Cr, up 4% YoY.
The company delivered exceptional full-year growth with margins expanding significantly, signaling strong operational leverage. Doubling of net profit and robust EBITDA growth are positive signals for shareholders, though the Q4 sequential slowdown in revenue growth (4% YoY) warrants monitoring.